Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRT811 · 1 trial · 2 indications
Dose limiting toxicities will be evaluated through the first cycle
The MTD will be established for further investigation in participants with solid tumors and gliomas
The RP2D will be established for further investigation in participants with solid tumors and gliomas
| Arm | Type | Description |
|---|---|---|
| PRT811 | EXPERIMENTAL | PRT811 will be administered orally |
| Name | Type | Description |
|---|---|---|
| PRT811 | DRUG | PRT811 will be administered orally |
Inclusion Criteria: * Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies * Subjects must have recovered from the effects of any prio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
PRT811 is an investigational small molecule being studied for the treatment of advanced solid tumors, including recurrent glioma. It is also being evaluated in central nervous system lymphoma. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
PRT811 is being developed by Prelude Therapeutics Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol PRLD. The company is conducting clinical research to evaluate the safety and efficacy of this investigational oncology drug.
PRT811 is in Phase 1 clinical development. A Phase 1 study of PRT811 in participants with advanced solid tumors, CNS lymphoma, and gliomas has been completed. The drug remains investigational and has not received regulatory approval.
PRT811 has been studied in a Phase 1 clinical trial identified as NCT04089449, titled "A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas." This trial enrolled 86 participants in the United States and has been completed.
PRT811 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is a distinct small molecule being developed by Prelude Therapeutics for oncology indications.